IQIYI Inc - ADR vs Oruka Therapeutics Inc. Common Stock — how do they compare? IQIYI Inc - ADR trades at $0.94 (market cap $962.85M), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 5.4× IQIYI Inc - ADR's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| IQ | ORKA | |
|---|---|---|
Market Cap | $962.85M | $5.18B |
Volume | 8,833,890 | 490,798 |
Sector | Media | Health |
52-Week High | $2.35 | $113.08 |
52-Week Low | $0.86 | $26.19 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | $2.46B | $4.31B |
Signals from Pluang's Aura AI — not financial advice
IQ trades at $0.9513, down 6.74% over 24 hours amid mixed signals. The stock shows a neutral technical stance with a bullish moving average trend but an overbought RSI. Fundamentally, the company reported a net loss of $206.31 million in 2025 despite beating EPS estimates in recent quarters, with revenue declining to $27.29 billion. Analyst sentiment is split, with 50% recommending buy. Recent news highlights iQIYI's push into AI-driven content, including new titles and revenue-sharing successes.
The outlook is cautious; while AI initiatives offer growth potential, persistent losses and revenue contraction pose risks. Valuation metrics like a high P/E of 144.05 suggest premium pricing relative to earnings, but low P/S and P/B ratios may attract value investors. Key risks include competitive pressures in streaming and reliance on AI content monetization. Investors should weigh innovation bets against financial sustainability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →